Family Turdidae (organism)
Ayrmid misses deadline for detailed offer to top private equity bid for bluebird
Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline
Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer
Ayrmid, Family Turdidae (organism), Twice a day, gene therapy, Carlyle, High, Bluebird Bio, Capital
Bluebird Bio’s Fall from Grace: Gene Therapy Pioneer Sells for $29M After $10B Valuation
Bluebird Bio, gene therapy, private equity, Carlyle, SK Capital, financial challenges, acquisition, biotech industry
National Resilience Lays Off 120 Employees at Former Bluebird Bio Gene Therapy Facility in Durham, North Carolina
National Resilience, Layoffs, Gene Therapy, Bluebird Bio, Durham/ North Carolina, Biotech Industry, CDMO (Contract Development and Manufacturing Organization)
Bluebird Bio Confronts Financial Crunch Amidst Breakeven Projections
Bluebird Bio, cash gap, breakeven point, financial stability, gene therapy, cash flow
Bluebird’s Struggles with Sickle Cell Gene Therapy Launch Impact Financial Stability
Bluebird Bio, sickle cell disease, gene therapy, Lyfgenia, loan rework, cash runway, financial stability
Bluebird Bio’s Fertility Support Program for Gene Therapies Rejected by HHS Inspector General
Bluebird Bio, Gene Therapy, Fertility Support, HHS Inspector General, Zynteglo, Skysona, Anti-Kickback Rules